13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001746382
Total reported value
$47.5M
$47.5M
63 檔
212.6%
As reported in its official Q4 2024 Form 13F filing, Altium Capital Management LLC's tracked investment portfolio stood at $47.5M with 63 total positions.
During Q4 2024, Altium Capital Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Establishment Labs Holdings In | Stock-Other | 7.91% | — | +361.83% | |
| 2 | ADMA | Adma Biologics Inc | Stock-Healthcare | 6.79% | — | +2.57% | |
| 3 | VERA | Vera Therapeutics Inc | Stock-Other | 5.18% | — | -36.84% | |
| 4 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 4.38% | — | -25.29% | |
| 5 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 4.38% | — | +8.82% | |
| 6 | SRRK | Scholar Rock Holding CORP | Stock-Other | 3.68% | — | — | |
| 7 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 3.46% | — | -25.68% | |
| 8 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.31% | — | -19.62% | |
| 9 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.19% | — | +17.42% | |
| 10 | CAPR | Capricor Therapeutics Inc | Stock-Other | 2.79% | — | +150.53% | |
| 11 | RXST | Rxsight Inc | Stock-Other | 2.78% | — | +154.46% | |
| 12 | MMSI | Merit Medical Systems Inc | Stock-Healthcare | 2.74% | — | +17.65% | |
| 13 | BHVN | Biohaven Ltd. | Stock-Other | 2.65% | — | +233.33% | |
| 14 | INSM | Insmed Inc | Stock-Healthcare | 2.58% | — | +1.54% | |
| 15 | RZLT | Rezolute Inc | Stock-Other | 2.35% | — | -0.35% | |
| 16 | EOLS | Evolus Inc | Stock-Other | 2.14% | — | +92.96% | |
| 17 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.78% | — | -51.30% | |
| 18 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.74% | — | — | |
| 19 | GKOS | Glaukos CORP | Stock-Healthcare | 1.70% | — | -48.05% | |
| 20 | RMD | Resmed Inc | Stock-Healthcare | 1.69% | — | — | |
| 21 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.67% | — | +15.87% | |
| 22 | EXK | Exact Sciences CORP | Stock-Materials | 1.59% | — | — | |
| 23 | LUNG | Pulmonx CORP | Stock-Other | 1.57% | — | +63.00% | |
| 24 | CMPS | Compass Pathways PLC | Stock-Other | 1.53% | — | — | |
| 25 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 1.51% | — | -33.77% | |
| 26 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 1.39% | — | -9.52% | |
| 27 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.39% | — | — | |
| 28 | SVRA | Savara Inc | Stock-Other | 1.37% | — | +0.25% | |
| 29 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 1.35% | — | -25.82% | |
| 30 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.29% | — | +97.44% | |
| 31 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.23% | — | -35.14% | |
| 32 | AVR | Anteris Technologies Global | Stock-Other | 1.17% | — | — | |
| 33 | PROF | Profound Medical CORP | Stock-Other | 1.03% | — | — | |
| 34 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.99% | — | +1.35% | |
| 35 | XTNT | Xtant Medical Holdings Inc | Stock-Other | 0.93% | — | — | |
| 36 | SKYE | Skye Bioscience Inc | Stock-Other | 0.91% | — | -13.39% | |
| 37 | ANAB | Anaptysbio Inc | Stock-Other | 0.84% | — | — | |
| 38 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.81% | — | — | |
| 39 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.81% | — | — | |
| 40 | NKTREUR | Nektar Therapeutics | Stock-Other | 0.79% | — | +26172.00% | |
| 41 | KROS | Keros Therapeutics Inc | Stock-Other | 0.79% | — | +153.62% | |
| 42 | IBRX | Immunitybio Inc | Stock-Healthcare | 0.77% | — | — | |
| 43 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 44 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.75% | — | +43.94% | |
| 45 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.74% | — | — | |
| 46 | EPIEUR | Essa Pharma Inc | Stock-Other | 0.73% | — | — | |
| 47 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.69% | — | — | |
| 48 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.53% | — | — | |
| 49 | ACOG | Alpha Cognition Inc | Stock-Other | 0.46% | — | — | |
| 50 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.43% | — | — |
According to official SEC Form 13F filings, Altium Capital Management LLC reported a total U.S. public equity portfolio value of $47.5M across 63 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ESTABLISHMENT LABS HOLDINGS IN, ADMA, VERA) accounted for 212.6% of total reported equity market value during Q4 2024.
During Q4 2024, Altium Capital Management LLC's top holdings by market value included ESTABLISHMENT LABS HOLDINGS IN (7.9%)、ADMA (6.8%)、VERA (5.2%). The largest single position, ESTABLISHMENT LABS HOLDINGS IN, represented 7.9% of total portfolio value.
In Q4 2024, Altium Capital Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.